BRIEF-Gilead Sciences gets Canada approval for Hepatitis C treatment Epclusa

Thu Jul 14, 2016 7:53am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

July 14 (Reuters) - Gilead Sciences Inc

* Gilead receives approval in Canada for Epclusa (sofosbuvir/velpatasvir), the first once-daily pan-genotypic (genotypes 1-6) single tablet regimen for the treatment of chronic Hepatitis C Source text for Eikon: Further company coverage: